Teva Inks Texas Opioids Settlement And Eyes J&J’s Nationwide ‘Formula’
Israeli Giant Spells Out ~$3bn Nationwide Settlement Ambition; Wants Deal In 2022
Executive Summary
Teva CEO Kåre Schultz has spoken at great length of the firm’s current standing with opioid-related matters, days after it reached a deal valued at $225m to resolve claims in the state of Texas. A nationwide deal is still top of the Israeli firm’s agenda, with a rough estimate of $3bn-$4bn suggested.
You may also be interested in...
Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds
Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.
Teva Inks $100m+ Deal To Settle West Virginia Opioid Claims
Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.
Teva Settles Opioid Litigation In Florida For $177m
Teva has settled the opioid claims it faced in the state of Florida, alongside CVS, Allergan and Endo.